Immunocore Stock Quote IMCR - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

34.80

Bid

35.13

Ask

36.86

Volume

1,226,938

35.06 Day's Range 36.00

0.00 52 Week Range 0.00

Market Cap

1.748B

Previous Close

35.94

Open

35.39

Last Trade

35.14

Last Trade Time

Financial Volume

$ 43,771,157

VWAP

35.6751

Average Volume (3m)

Shares Outstanding

49,726,000

Dividend Yield

PE Ratio

-31.62

Earnings Per Share (EPS)

-1.11

Revenue

249.43M

Net Profit

-55.29M

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority o... Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States. Show more

Sector

Noncomml Resh Organizations

Industry

Noncomml Resh Organizations

Website

www.immunocore.com

Headquarters

Oxfordshire, Gbr

Founded

1970

Immunocore Holdings PLC is listed in the Noncomml Resh Organizations sector of the NASDAQ with ticker IMCR. The last closing price for Immunocore was $35.94. Over the last year, Immunocore shares have traded in a share price range of $ 0.00 to $ 0.00.

Immunocore currently has 49,726,000 shares outstanding. The market capitalization of Immunocore is $1.75 billion. Immunocore has a price to earnings ratio (PE ratio) of -31.62.

Overall Flow

Bullish

Net Premium

35k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous...

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...

Form 8-K - Current report

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...

Immunocore to present at the Jefferies Global Healthcare Conference

Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 May 2024) Immunocore Holdings plc (Nasdaq: IMCR...

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GRDIGRIID Infrastructure Inc	$ 1.11 (98.21%)	155.62M
ZAPPZapp Electric Vehicles Group Ltd	$ 2.33 (71.32%)	91.48M
MGOLMGO Global Inc	$ 0.725 (58.16%)	160.26M
RELIReliance Global Group Inc	$ 0.61 (55.97%)	139.37M
HAOHaoxi Health Technology Ltd	$ 6.36 (38.26%)	693.04k
WHLRWheeler Real Estate Investment Trust Inc	$ 2.75 (-82.51%)	164.01k
KAVLKaival Brands Innovations Group Inc	$ 2.90 (-35.56%)	1.31M
MBIOMustang Bio Inc	$ 0.5605 (-34.07%)	38.18M
SONNSonnet BioTherapeutics Holdings Inc	$ 1.04 (-32.03%)	432.19k
NKLANikola Corporation	$ 0.3279 (-31.82%)	269.8M
NVDANVIDIA Corporation	$ 130.78 (-3.54%)	518.05M
NKLANikola Corporation	$ 0.3279 (-31.82%)	269.8M
SMXSMX Security Matters Public Company	$ 0.16 (34.45%)	177.78M
SQQQProShares UltraPro Short QQQ	$ 8.32 (2.46%)	166.95M
MGOLMGO Global Inc	$ 0.725 (58.16%)	160.26M